2 year recurrence free survival benefit for resectable melanoma treated with neoadjuvant/adjuvant pembrolizumab
Dr Prateek Jain speaks to ecancer about a retrospective analysis regarding the outcomes of clinico-radiologically advanced cancer (cT4b) of the buccal mucosa.
He says that in this study data from 104 patients who were staged cT4b and underwent upfront surgery for squamous cell carcinoma of
buccal mucosa was retrospectively analysed.
Dr Jain explains the methodology of the study next and then talks about the results.
He concludes by saying that upfront surgery is a feasible option for patients with carcinoma of the buccal mucosa with the involvement of the masticator space.
Survival outcomes are better in patients where resection is achieved with clear margins, and regional disease is limited to a single cervical lymph node.
See the study here.
2 year recurrence free survival benefit for resectable melanoma treated with neoadjuvant/adjuvant pembrolizumab
Rationale for routine use of IORT for early breast cancer and data for specific indications
The advantages of IORT for early breast cancer treatment
Durable effect of imatinib and metronomic chemotherapy with capecitabine in pancreatic carcinoma
Intraoperative radiotherapy treatment in the Philippines
The pros and cons of breast IORT and ultra hypofractionation (FR)
War in Ukraine: The logistical challenges of transferring medical materials
Rationale for routine use of IORT for early breast cancer and data for specific indications
Global adoption of single-shot targeted IORT for breast cancer